Lupin Limited reported a 37.4 percent year-on-year increase in net profit for the third quarter ended December 31, 2025, reaching INR 1,180.5 crore, compared with INR 858.9 crore in the same quarter last year.

Revenue from operations grew 24.3 percent to INR 7,167.5 crore from INR 5,767.8 crore a year earlier. The company invested INR 535.2 crore in research and development during the quarter, equivalent to 7.5 percent of sales, highlighting its continued focus on innovation.

Managing Director Nilesh Gupta said the company delivered another strong quarter, driven by its highest-ever quarterly US sales and double-digit growth across key regions, keeping it on track for a solid FY26 close.

US sales — contributing 44 percent of global revenue — rose 54 percent year-on-year to INR 3,113.2 crore. India sales, accounting for 29 percent of global revenue, increased 5.6 percent to INR 2,038.7 crore. Other developed markets grew 10.8 percent to INR 812.1 crore, while emerging markets posted 42.4 percent growth to INR 917 crore.

The formulations segment expanded 29.1 percent to INR 6,881 crore, while the active pharmaceutical ingredients business recorded 26.4 percent growth compared with the year-ago period.

During the quarter, the company received one ANDA approval from the US regulator and launched three products in the US, taking its marketed generics portfolio there to 149 products. As of December 31, 2025, cumulative ANDA filings stood at 431, with 341 approvals received. Lupin also holds 52 First-to-File filings, including 22 exclusive opportunities, and has filed 93 US Drug Master Files.